含有levodopa的纳米粒子用于治疗帕金森病
Emile F van Vliet1, Maarten J Knol1, Raymond M Schiffelers2
1Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, the Netherlands.
概括
纳米粒子 (NP) 封装的利沃多巴 (L-DOPA) 提供了改善的脑传递帕金森病 (PD) 治疗. 这种方法可以提高多巴胺水平,减少副作用,并探索新的输送途径,以获得更好的治疗结果.
科学领域:
- 神经科学是一个神经科学.
- 生物医学工程 生物医学工程
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森病 (PD) 涉及由于神经退行导致多巴胺缺乏,导致运动症状.
- 目前的口服利沃多巴 (L-DOPA) 治疗效率低下,需要更高的剂量,并引起诸如动症等副作用.
研究的目的:
- 审查纳米粒子 (NP) 中介的L-DOPA在帕金森病的治疗中取得的最新进展.
- 探索增强L-DOPA向大脑输送和减少系统性副作用的策略.
主要方法:
- 将L-DOPA封装成基于聚合物和脂质的纳米粒子 (NP).
- 修改NP以针对血脑屏障 (BBB) 的目标部分.
- 评估其他输送途径:静脉注射 (IV),通过皮肤和鼻内注射.
主要成果:
- NP配方保护L-DOPA免受系统降解,并改善中枢神经系统的输送.
- 有针对性的NP和替代的输送方法会增加大脑中的治疗性多巴胺度.
- 降低L-DOPA剂量和全身多巴胺水平是可以实现的,减轻副作用.
结论:
- 通过纳米粒子介导的L-DOPA输送显示了改善帕金森病治疗疗效的显著前景.
- 需要进一步的研究和开发来应对挑战,并优化基于NP的疗法用于临床应用.
相关概念视频
01:24Parkinson's Disease: Treatment
303
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
303
01:15Parkinson's Disease: Overview
607
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
607